Back
31/10/2024

Measurable Residual Disease and Decision-Making in Multiple Myeloma

Benjamin A. Derman &  Rafael Fonseca. Hematol Oncol Clin N Am. 2024:38:477–495. https://doi.org/10.1016/j.hoc.2023.12.009

An excellent, must-read review article has been published by Benjamin Derman and Rafael Fonseca with a deep-dive into the evolving technical aspects of MRD testing and impact when implementing MRD-adapted decision-making in clinical practice.

Share this article with your colleagues

MAT-BE-2401002 (ver.1) 11 2024

Vorig bericht

Hypogammaglobulinemia newsletter

Volgend bericht

Frailty in multiple myeloma